What is a stock summary page? Click here for an overview.
Business Description
Adverum Biotechnologies Inc
NAICS : 325412
SIC : 2834
ISIN : US00773U1088
Description
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.09 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.51 | |||||
| Debt-to-EBITDA | -0.74 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -5.79 | |||||
| Beneish M-Score | -3.1 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 4.2 | |||||
| 3-Year EPS without NRI Growth Rate | 5.6 | |||||
| 3-Year FCF Growth Rate | 5.3 | |||||
| 3-Year Book Growth Rate | -43 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 26.98 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.33 | |||||
| 9-Day RSI | 61.14 | |||||
| 14-Day RSI | 58.87 | |||||
| 3-1 Month Momentum % | -17.03 | |||||
| 6-1 Month Momentum % | -46.91 | |||||
| 12-1 Month Momentum % | -74.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.82 | |||||
| Quick Ratio | 5.82 | |||||
| Cash Ratio | 5.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.3 | |||||
| Shareholder Yield % | -86.49 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -10310 | |||||
| Net Margin % | -9411.1 | |||||
| FCF Margin % | -8606 | |||||
| ROE % | -69.14 | |||||
| ROA % | -41.8 | |||||
| ROIC % | -113.57 | |||||
| 3-Year ROIIC % | -13.91 | |||||
| ROC (Joel Greenblatt) % | -157.16 | |||||
| ROCE % | -51.53 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 108.49 | |||||
| PB Ratio | 0.75 | |||||
| Price-to-Tangible-Book | 0.74 | |||||
| EV-to-EBIT | -0.25 | |||||
| EV-to-Forward-EBIT | -0.05 | |||||
| EV-to-EBITDA | -0.27 | |||||
| EV-to-Forward-EBITDA | -0.05 | |||||
| EV-to-Revenue | 26.43 | |||||
| EV-to-Forward-Revenue | 24.32 | |||||
| EV-to-FCF | -0.42 | |||||
| Price-to-Net-Current-Asset-Value | 1.5 | |||||
| Price-to-Net-Cash | 1.69 | |||||
| Earnings Yield (Greenblatt) % | -394.79 | |||||
| FCF Yield % | -80.89 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Adverum Biotechnologies Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1 | ||
| EPS (TTM) ($) | -6.01 | ||
| Beta | -1.01 | ||
| 3-Year Sharpe Ratio | -0.02 | ||
| 3-Year Sortino Ratio | -0.04 | ||
| Volatility % | 49.91 | ||
| 14-Day RSI | 58.87 | ||
| 14-Day ATR ($) | 0.387655 | ||
| 20-Day SMA ($) | 4.57466 | ||
| 12-1 Month Momentum % | -74.1 | ||
| 52-Week Range ($) | 3.7614 - 16.4855 | ||
| Shares Outstanding (Mil) | 20.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Adverum Biotechnologies Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Adverum Biotechnologies Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Adverum Biotechnologies Inc Frequently Asked Questions
What is Adverum Biotechnologies Inc(LTS:0HA3)'s stock price today?
The current price of LTS:0HA3 is $5.29. The 52 week high of LTS:0HA3 is $16.49 and 52 week low is $3.76.
When is next earnings date of Adverum Biotechnologies Inc(LTS:0HA3)?
The next earnings date of Adverum Biotechnologies Inc(LTS:0HA3) is 2025-03-25 Est..
Does Adverum Biotechnologies Inc(LTS:0HA3) pay dividends? If so, how much?
Adverum Biotechnologies Inc(LTS:0HA3) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers